Martin J Yaffe1, Nicole Mittmann2, Pablo Lee3, Anna N A Tosteson4, Amy Trentham-Dietz5, Oguzhan Alagoz6, Natasha K Stout7. 1. Physical Sciences Program, Sunnybrook Research Institute; Departments of Medical Biophysics and Medical Imaging, University of Toronto. 2. Cancer Care Ontario. 3. Institute for Technology Assessment, Massachusetts General Hospital. 4. Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth. 5. Department of Population Health Sciences and Carbone Cancer Center, University of Wisconsin. 6. Department of Population Health Sciences and Carbone Cancer Center and the Department of Industrial and Systems Engineering, University of Wisconsin. 7. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute.
Abstract
BACKGROUND: A validated breast cancer model can be used to compare health outcomes associated with different screening strategies. DATA AND METHODS: The University of Wisconsin Cancer Intervention and Surveillance Modeling Network (CISNET) breast cancer microsimulation model was adapted to simulate breast cancer incidence, screening performance and delivery of optimal therapies in Canada. The model considered effects of breast density on incidence and screening performance. Model predictions of incidence, mortality and life-years (LY) gained for a 1960 birth cohort of women for No Screening were compared with 11 digital mammography screening strategies that varied by starting and stopping age and frequency. RESULTS: In the absence of screening, the estimate of LYs lost from breast cancer was 360.1 per 1,000 women, and each woman diagnosed with breast cancer after age 40 who dies of breast cancer would lose an average of 19.1 years. Biennial screening at ages 50 to 74 resulted in 116.3 LYs saved. Annual screening at ages 40 to 49, followed by biennial screening to age 74, resulted in 170.3 LY saved. Screening annually at ages 40 to 74 recovered the most: 214 LY saved. Annual screening at age 40 resulted in 54 LY gained per 1,000 women. More frequent screening was associated with an increased ratio of detection of ductal in situ to invasive cancers, more abnormal recalls and more negative biopsies, but a reduction in the number of women required to be screened per life saved or per LY saved. INTERPRETATION: In general, mortality reduction was found to be associated with the total number of lifetime screens for breast cancer. However, for the same number of screens, more frequent screening after age 50 appeared to have a greater impact than beginning screening earlier. When the number of LYs saved by screening was considered, a greater impact was achieved by screening women in their 40s than by reducing the interval between screens.
BACKGROUND: A validated breast cancer model can be used to compare health outcomes associated with different screening strategies. DATA AND METHODS: The University of Wisconsin Cancer Intervention and Surveillance Modeling Network (CISNET) breast cancer microsimulation model was adapted to simulate breast cancer incidence, screening performance and delivery of optimal therapies in Canada. The model considered effects of breast density on incidence and screening performance. Model predictions of incidence, mortality and life-years (LY) gained for a 1960 birth cohort of women for No Screening were compared with 11 digital mammography screening strategies that varied by starting and stopping age and frequency. RESULTS: In the absence of screening, the estimate of LYs lost from breast cancer was 360.1 per 1,000 women, and each woman diagnosed with breast cancer after age 40 who dies of breast cancer would lose an average of 19.1 years. Biennial screening at ages 50 to 74 resulted in 116.3 LYs saved. Annual screening at ages 40 to 49, followed by biennial screening to age 74, resulted in 170.3 LY saved. Screening annually at ages 40 to 74 recovered the most: 214 LY saved. Annual screening at age 40 resulted in 54 LY gained per 1,000 women. More frequent screening was associated with an increased ratio of detection of ductal in situ to invasive cancers, more abnormal recalls and more negative biopsies, but a reduction in the number of women required to be screened per life saved or per LY saved. INTERPRETATION: In general, mortality reduction was found to be associated with the total number of lifetime screens for breast cancer. However, for the same number of screens, more frequent screening after age 50 appeared to have a greater impact than beginning screening earlier. When the number of LYs saved by screening was considered, a greater impact was achieved by screening women in their 40s than by reducing the interval between screens.
Entities:
Keywords:
Breast screening; health outcomes; microsimulation model; preventive health
Authors: Marcello Tonelli; Sarah Connor Gorber; Michel Joffres; James Dickinson; Harminder Singh; Gabriela Lewin; Richard Birtwhistle; Donna Fitzpatrick-Lewis; Nicole Hodgson; Donna Ciliska; Mary Gauld; Yan Yun Liu Journal: CMAJ Date: 2011-11-22 Impact factor: 8.262
Authors: Natasha K Stout; Marjorie A Rosenberg; Amy Trentham-Dietz; Maureen A Smith; Stephen M Robinson; Dennis G Fryback Journal: J Natl Cancer Inst Date: 2006-06-07 Impact factor: 13.506
Authors: Anna N A Tosteson; Natasha K Stout; Dennis G Fryback; Suddhasatta Acharyya; Benjamin A Herman; Lucy G Hannah; Etta D Pisano Journal: Ann Intern Med Date: 2008-01-01 Impact factor: 25.391
Authors: Dennis G Fryback; Natasha K Stout; Marjorie A Rosenberg; Amy Trentham-Dietz; Vipat Kuruchittham; Patrick L Remington Journal: J Natl Cancer Inst Monogr Date: 2006
Authors: Heidi D Nelson; Kari Tyne; Arpana Naik; Christina Bougatsos; Benjamin K Chan; Linda Humphrey Journal: Ann Intern Med Date: 2009-11-17 Impact factor: 25.391
Authors: Martin J Yaffe; Nicole Mittmann; Pablo Lee; Anna N A Tosteson; Amy Trentham-Dietz; Oguzhan Alagoz; Natasha K Stout Journal: Health Rep Date: 2015-12 Impact factor: 4.796
Authors: Carlos Canelo-Aybar; Margarita Posso; Nadia Montero; Ivan Solà; Zuleika Saz-Parkinson; Stephen W Duffy; Markus Follmann; Axel Gräwingholt; Paolo Giorgi Rossi; Pablo Alonso-Coello Journal: Br J Cancer Date: 2021-11-26 Impact factor: 9.075